Vanguard Personalized Indexing Management LLC Grows Position in Pfizer Inc. $PFE

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in Pfizer Inc. by 26.4%, acquiring a total of 504,446 shares worth about $12.23 million as of their latest SEC filing.
• Pfizer reported $14.65 billion in revenue for the last quarter, exceeding estimates and reflecting a 10.3% increase year-over-year, while earning $0.78 EPS against a consensus estimate of $0.58.
• The company announced a quarterly dividend of $0.43, payable on December 1st, with a current dividend yield of 6.9%.

Vanguard Personalized Indexing Management LLC increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 26.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 504,446 shares of the biopharmaceutical company's stock after purchasing an additional 105,453 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Pfizer were worth $12,230,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Capital Advisory Group Advisory Services LLC boosted its stake in shares of Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after buying an additional 388 shares during the last quarter. Citizens National Bank Trust Department boosted its stake in shares of Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock worth $1,118,000 after buying an additional 395 shares during the last quarter. Trust Co of the South boosted its stake in shares of Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after buying an additional 441 shares during the last quarter. Charter Oak Capital Management LLC boosted its stake in shares of Pfizer by 4.3% in the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after buying an additional 444 shares during the last quarter. Finally, Ballentine Partners LLC boosted its stake in shares of Pfizer by 0.5% in the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company's stock worth $2,260,000 after buying an additional 458 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.81 on Monday. The stock's 50-day simple moving average is $24.86 and its 200-day simple moving average is $24.12. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.82. The company has a market capitalization of $141.03 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.82 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the business earned $0.60 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer's payout ratio is 91.49%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PFE. Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Bank of America lifted their target price on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Morgan Stanley lowered their target price on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $28.35.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.